Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lexeo Therapeutics
Biotech
Lexeo laid off 15% in April to focus on cardiac gene therapies
Lexeo laid off 15% of staff last month as part of a wider plan to siphon $20 million from its wider pipeline to fund its lead cardiac programs.
James Waldron
May 12, 2025 8:30am
Lexeo locks in pivotal trial plan as gene therapy data accrue
Apr 7, 2025 9:37am
Lexeo links gene therapy to improvements in rare heart disease
Jul 15, 2024 9:46am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
Lexeo drops share price at last minute to raise $100M IPO
Nov 3, 2023 8:19am
Two biotechs go public while Apnimed bides its time
Oct 2, 2023 11:02am
